Abstract:Not Provided THE ROLE OF THE 5-HT 2C RECEPTOR IN SATIETY AND IN THE MECHANISM OF ACTION OF ANORECTIC DRUGS Clifton PG . Expenmental Psychology, Sussex University, Brighton BN1 9QG, UK A causal relationship between enhanced serotonergic activity and the onset of behavioural satiety during ingestive behaviour was postulated by Blundell (Appetite, 7, 39-56, 1986) I shall review recent studies using a vanety of behavioural tasks that support Blundell’s original hypothesis and suggest that the 5-HTZC receptor has an important role m mediating such effects Thus, mice with non-functional 5-HT2C receptors show impaired satiety responses and become mildly obese A preferentially selective 5-HT2c agonist, Ro 60-0175, reduces food intake and advances the behavioural satiety sequence in both rats and mice It also seems likely that actions at 5-HT2c receptors mediate, to a substantial extent, the hypophagic effect of drugs such as dfenfluramme The metabolite, d-norfenfluramine, is a potent 5-HT2c agonist Detailed compansons of the behavioural action of Ro 600175 and d-fenfluramine in meal patterning and lick patterning paradigms show considerable similarity at equi-anorectic doses Mice with non-functional 5-HT2c receptors are relatively unresponsive to the hypophagic action of d-fenfluramine However it must be recognls~d that any suggestion of an exclusme link between a receptor subtype and some behavioural outcome is likely to be as misleading as earlier attempts to suggest such links between particular brain structures or neurotransmitters and specific categones of behaviour Nevertheless the empirical studies reviewed here do suggest that the 5-HT2c receptor represents a rational target for pharmacological intervention in body weight regulation GLP-1 AND OBESITY Bloom SR Division of Investigative Science, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Road, London W 12 ONN Over the last five years there have been major advances m our understanding of the hypothalamic mechanisms controlling appetite. Glucagon Like Peptide 1 7-36 amide (GLP-1 ), is a product of the glucagon pro-hormone Whereas in the alpha cell of the pancreas this translational enzyme processing produces glucagon but not GLP-1, the opposite is true in the CNS Here GLP-1 is synthesised m neurons m the dorsal vagal complex and transported to the paraventricular nucleus of the hypothalamus The GLP-1 receptor has been cloned and is a 7 transmembrane G protem receptor It is found in the CNS m high concentrations m the hypothalamus Only one subtype has so far been identified In order to identify the possible physiological role of hypothalamic GLP-1, we injected it intracerebroventricularly (ICV) There was a dramatic, dose-dependent, inhibition of food intake lastmg several hours The peptide exendin 9-39 has been identified as a potent GLP-1 antagomst, active in a ratio of 1:20. When exendin is infused ICV it has no effect on fasting rats, but satiated rats begm to feed agam and significantly mcrease their total intake This suggests that release of endogenous GLP-1 occurs in satiety and that GLP 1 is a hormone of satiety (Turton MD et al 1996 Nature 379 69-72) Subsequently, a number of different animal models of overfeeding have been tested and in each, GLP-1 reduces food intake and exendin 9-39 increases it In order to identify which neuronal circuits are activated by GLP-1, brain sections were stained for the immediate early gene, cfos, and activated neurons were only found in the central nucleus of the amygdala and paraventncular nucleus (both areas concerned with food intake) Thus, it seems likely that GLP-1 is an inhibitor of food intake, which is endogenously released m satiety.

Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite

Molecular Connectomics Reveals a Glucagon-Like Peptide 1 Sensitive Neural Circuit for Satiety

Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

GLP-1 increases preingestive satiation via hypothalamic circuits in mice and humans

Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice

Endogenous Glucagon-like Peptide-1 Suppresses High-Fat Food Intake by Reducing Synaptic Drive Onto Mesolimbic Dopamine Neurons

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

Does Incretin Agonism Have Sustainable Efficacy?

A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity

Dissociable hindbrain GLP1R circuits for satiety and aversion

Enhanced AMPA Receptor Trafficking Mediates the Anorexigenic Effect of Endogenous Glucagon-like Peptide-1 in the Paraventricular Hypothalamus

A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs

Stimulating intestinal GIP release reduces food intake and body weight in mice

105-OR: Single-Cell Multiomic Analysis of the Effect of GIP and GIP-1 Mono- and Multi-agonism on the Hypothalamus and Hindbrain

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models

Abstract Not Provided

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists

The incretin/glucagon system as a target for pharmacotherapy of obesity

Opioidergic Regulation of AgRP Neurons

Brain access of incretins and incretin receptor agonists to their central targets relevant for appetite suppression and weight loss.